

For immediate release

15 February 2006

**Maelor plc**

The Directors of Maelor note the recent rise in the Company's share price and are not aware of any specific external events that may have caused the rise.

During the week, the Company achieved the return in-house of Volplex, Maelor's treatment for hypovolaemia, enabling the Company to focus directly on increasing sales and market share. Despite the de-stocking process involved in returning Volplex from a distributor, Company turnover for the second half of the year is anticipated to be in line with the levels seen in the first six months. Operating losses are likely to half in the final six months of the year relative to the first six months, ahead of expectations.

The Directors are pleased with the progress of the recently announced strategic review, which they expect to complete on schedule and be in a position to update the market in parallel with year end results.

Further information:

Tim Wright, CEO Maelor plc  
01978 810 153

Ben Atwell, Financial Dynamics  
020 7831 3113